Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease

doi:10.4254/wjh.v16.i1.75

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3479)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1658

Figures (1-4)

200

Tables (1-5)

217

Sum=2161

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

141

Download

420

Sum=561

Publishing Process of This Article

Item

Count

Browse

243

Download

416

Sum=659

Jan 27, 2024 (publication date) through Dec 28, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Jan 27, 2024; 16(1): 75-90
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.75

Table 1 Gene expression of markers related to hepatocarcinogenesis

Variables¹	Control (n = 8)	HCC (n = 7)	RIF (n = 7)	P value
Tuba1c	1.28 (0.18-2.76)	4.27 (0.00-9.69)	1.38 (0.29-19.8)	0.839
Aldob	2.46 (0.01-5.78)	4.24 (0.00-9.92)	0.12 (0.00-2.69)	0.595
Afp	1.28 (0.18-2.76)	2.33 (0.00-9.69)	1.38 (0.29-19.8)	0.837
Mmp2	1.81 (0.03-5.15)	31.4 (0.25-62.2)	0.92 (0.16-18.4)	0.101
Mmp9	2.36 (0.02-4.25)^a	23.6 (2.69-76.8)^b	14.6 (1.32-28.7)^a^,^b	0.035
miR-122	1.14 (0.34-2.34)^a	7.07 (1.41-11.8)^b	2.62 (1.20-6.00)^a^,^b	0.005
miR-34a	0.94 (0.63-1.70)^b	0.39 (0.33-0.44)^a	0.33 (0.13-0.89)^a	0.007
miR-26b	1.04 (0.61-1.57)^a^,^b	0.36 (0.21-1.85)^a	2.22 (1.46-2.96)^b	0.026
miR-224	1.05 (0.41-2.45)^a^,^b	2.97 (1.96-5.94)^b	0.58 (0.13-0.85)^a	0.005
miR-33a	0.98 (0.53 – 2.16)	0.60 (0.54-1.17)	1.4 (0.70-1.60)	0.445
miR-143	1.18 (0.25-3.67)	1.40 (0.54-5.16)	0.62 (0.17-2.54)	0.471
miR-155	1.46 (0.32-1.96)	0.63 (0.01-1.18)	0.34 (0.04-1.46)	0.074
miR-375	0.79 (0.61-2.42)	0.85 (0.17-1.09)	0.38 (0.14-1.76)	0.216
miR-21	1.12 (0.34-2.13)	1.49 (0.91-6.08)	1.69 (0.84-3.68)	0.188

¹Variables expressed by median (25^th–75^th percentiles).

^aP < 0.05. Different letters indicate a significant difference between groups.

^bP < 0.05. Different letters indicate a significant difference between groups.

HCC: Hepatocellular carcinoma; RIF: Rifaximin; Afp: Alpha-fetoprotein; Aldo-B: Aldolase-B; Mmp: Metalloproteinases; Tuba1c: Tubulin alpha-1c.

Citation: Michalczuk MT, Longo L, Keingeski MB, Basso BS, Guerreiro GTS, Ferrari JT, Vargas JE, Oliveira CP, Uribe-Cruz C, Cerski CTS, Filippi-Chiela E, Álvares-da-Silva MR. Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease. World J Hepatol 2024; 16(1): 75-90
URL: https://www.wjgnet.com/1948-5182/full/v16/i1/75.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i1.75